Kristen Fortney, PhD, CEO and co-founder, is scheduled to participate in a fireside chat on Thursday, February 26 from 10:40 AM to 11:05 AM ET. Fortney and Dov Goldstein, MD, CFO, will participate in ...

(Reuters) -BioAge Labs is eyeing a valuation of up to $639.7 million in its upsized initial public offering in the United States, the obesity drug developer said on Wednesday, in a sign of strong ...

Sept 26 (Reuters) - Shares of BioAge Labs (BIOA.O), opens new tab opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the ...

Fintel reports that on February 18, 2026, Jefferies upgraded their outlook for BioAge Labs (NasdaqGS:BIOA) from Hold to Buy. Analyst Price Forecast Suggests 41.59% Upside As of February 4, 2026, the ...

After raising $170 million back in February, metabolic disease-focused BioAge Labs has filed to debut on the public market. The Eli Lilly-partnered biotech hopes to list on the Nasdaq under the symbol ...

BioAge Labs is eyeing around $180 million in initial proceeds from an IPO and a private placement, funds the metabolic-focused biotech will use to push its lead obesity prospect through the clinic.

BioAge Labs' leading candidate is far too early in the process to make reliable predictions. The biotech will encounter plenty of challengers in its chosen therapeutic area. BioAge Labs (NASDAQ: BIOA) ...

BioAge Labs is having its initial public offering today. The drug developer’s signature product, Azelaprag, isn’t yet on sale, but it is undergoing clinical trials in hopes it will one day be. What ...

BioAge Labs Inc, a biotech focused on developing therapies for metabolic diseases, filed an SEC filing to raise up to $100 million in an initial public offering. The company was founded in 2015 and ...

The average one-year price target for BioAge Labs (NasdaqGS:BIOA) has been revised to $27.80 / share. This is an increase of 127.08% from the prior estimate of $12.24 dated January 11, 2026. The price ...

The biotech sector is reviving, with IPOs reappearing and BioAge Labs' weight loss drug, Azelaprag, showing market potential. Biotech stocks are volatile, facing challenges like regulatory hurdles and ...

BioAge now offering 10.5 mln shares, vs 7.5 mln earlier Sofinnova expected to invest up to $1.4 mln in IPO Investment firm expected to buy shares worth $10.6 mln in private placement Sept 25 (Reuters) ...